Cargando…
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
AIM: To assess the efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD) inadequately controlled by insulin. MATERIALS AND METHODS: VERTIS CV was the cardiovascular outcome study for ertugliflozin. Patient...
Autores principales: | Lingvay, Ildiko, Greenberg, Michelle, Gallo, Silvina, Shi, Harry, Liu, Jie, Gantz, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252001/ https://www.ncbi.nlm.nih.gov/pubmed/33769675 http://dx.doi.org/10.1111/dom.14385 |
Ejemplares similares
-
Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021) -
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
por: Dagogo-Jack, Samuel, et al.
Publicado: (2023) -
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2020) -
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2022) -
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
por: Wojeck, Brian S., et al.
Publicado: (2022)